Analyst Price Targets — VSTM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 19, 2026 12:18 pm | — | Mizuho Securities | $18.00 | $5.71 | TheFly | Verastem price target raised to $18 from $15 at Mizuho |
| October 29, 2025 12:51 pm | — | Mizuho Securities | $15.00 | $8.85 | TheFly | Verastem price target raised to $15 from $14 at Mizuho |
| October 21, 2025 2:08 pm | Graig Suvannavejh | Mizuho Securities | $14.00 | $8.12 | StreetInsider | Mizuho Reiterates Outperform Rating on Verastem (VSTM) |
| October 21, 2025 10:48 am | Swayampakula Ramakanth | H.C. Wainwright | $14.00 | $8.02 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM) |
| October 20, 2025 4:16 pm | — | RBC Capital | $13.00 | $8.01 | TheFly | Verastem data 'best-in-class' despite slight decline, says RBC Capital |
| March 24, 2025 11:30 am | Michael Schmidt | Guggenheim | $14.00 | $6.88 | TheFly | Verastem price target raised to $14 from $13 at Guggenheim |
| March 24, 2025 10:09 am | — | H.C. Wainwright | $10.00 | $6.88 | TheFly | Verastem price target raised to $10 from $7 at H.C. Wainwright |
| July 29, 2024 7:15 am | Graig Suvannavejh | Mizuho Securities | $7.00 | $2.77 | StreetInsider | Verastem (VSTM) PT Lowered to $7 at Mizuho |
| May 24, 2024 12:29 pm | Justin Zelin | BTIG | $13.00 | $4.12 | StreetInsider | Verastem (VSTM) PT Lowered to $13 at BTIG |
| April 15, 2022 1:40 pm | Gregory Renza | RBC Capital | $5.00 | $1.77 | Pulse 2.0 | Verastem (VSTM) Stock: Why The Price Surged Over 25% Today |
Latest News for VSTM
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results and business updates on Wednesday, March 4, 2026, at 4:30 pm ET. To access the conference call, please…
Verastem (VSTM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Verastem (NASDAQ: VSTM) executives highlighted commercial momentum for the company's newly launched ovarian cancer therapy and laid out near-term clinical catalysts across its RAS-pathway pipeline during a fireside chat hosted by Guggenheim Senior Biotech Analyst Michael Schmidt. President and CEO Dan Paterson and Chief Scientific Officer Jonathan Pachter discussed uptake of the company's low-grade serous ovarian
VSTM shares rise nearly 8% after the release of preliminary fourth-quarter 2025 and full-year 2025 sales numbers, driven by Avmapki Fakzynja Co-pack.
Pre-Market Stock Futures: Futures are trading mixed this morning after a dreadful day across Wall Street, with all major indices closing lower except the Russell 2000. What began in late December and has gained considerable traction recently is the narrative of a broad rotation out of technology stocks. For the last three years, technology stocks,... Here Are Wednesday's Top Wall Street Analyst Research Calls: AES…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VSTM.
U.S. House Trading
No House trades found for VSTM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.